Research Topics
Genomes and GenesSpecies | ANNE SEARLS DE GROOTSummaryAffiliation: Brown University Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Further progress on defining highly conserved immunogenic epitopes for a global HIV vaccine: HLA-A3-restricted GAIA vaccine epitopesAnne S De Groot
EpiVax, Inc, Providence, RI, USA
Hum Vaccin Immunother 8:987-1000. 2012..Validation of these HLA-A3 epitopes conserved across time, clades, and geography supports the hypothesis that epitopes such as these would be candidates for inclusion in our globally relevant GAIA HIV vaccine constructs...
Immunomics: discovering new targets for vaccines and therapeuticsAnne S De Groot
EpiVax, 146 Clifford Street, Providence, RI 02903, USA
Drug Discov Today 11:203-9. 2006..This review highlights aspects of recent immunomics research that are related to the discovery of the T-cell immunome...
HIV vaccine development by computer assisted design: the GAIA vaccineAnne S De Groot
TB HIV Research Laboratory, Brown University, Providence, RI 02912, USA
Vaccine 23:2136-48. 2005..These data confirm the utility of bioinformatics tools to design novel vaccines containing "immunogenic consensus sequence" T cell epitopes for a globally relevant vaccine against HIV...
Prediction of immunogenicity for therapeutic proteins: state of the artAnne S De Groot
Brown Medical School, Box G A, 97 Waterman Street, Providence, RI 02912, USA
Curr Opin Drug Discov Devel 10:332-40. 2007....
Analysis of ChimeriVax Japanese Encephalitis Virus envelope for T-cell epitopes and comparison to circulating strain sequencesAnne S De Groot
Brown University, Providence, RI 02912, United States
Vaccine 25:8077-84. 2007..Based on this analysis, we predict no significant abrogation of ChimeriVax-JEV-conferred protection against circulating JEV strains...
Identification of immunogenic HLA-B7 "Achilles' heel" epitopes within highly conserved regions of HIVAnne S De Groot
EpiVax, Inc, Providence, RI 02903, USA
Vaccine 26:3059-71. 2008..The most immunogenic of these epitopes will be included in the GAIA multi-epitope vaccine...
Prediction of immunogenicity: in silico paradigms, ex vivo and in vivo correlatesAnne S De Groot
EpiVax, Inc, University of Rhode Island, Providence, RI, USA
Curr Opin Pharmacol 8:620-6. 2008....
Reducing risk, improving outcomes: bioengineering less immunogenic protein therapeuticsAnne S De Groot
EpiVax, Inc, Providence, RI 02903, USA
Clin Immunol 131:189-201. 2009..Recommendations for Td immunogenicity screening and assessment provided in this article may contribute to the development of safer protein-based drugs for human use...
Immunoinformatic comparison of T-cell epitopes contained in novel swine-origin influenza A (H1N1) virus with epitopes in 2008-2009 conventional influenza vaccineAnne S De Groot
EpiVax, 146 Clifford Street, Providence, RI 02903, USA
Vaccine 27:5740-7. 2009....
Modelling the immunogenicity of therapeutic proteins using T cell epitope mappingA S De Groot
EpiVax, Inc, Providence, RI 02906, USA
Dev Biol (Basel) 112:71-80. 2003....
A comparison of two methods for T cell epitope mapping: "cell free" in vitro versus ImmunoinformaticsTimothy James Messitt
EpiVax, Inc, Providence, RI, USA and Institute for Immunology and Informatics, University of Rhode Island, Providence, RI, USA
Immunome Res 7:6. 2011..Although the cell-free system allows assessment of intracellular processing, the in silico approach is higher throughput, and can be performed much faster with far fewer resources...
Evolutionary deimmunization: an ancillary mechanism for self-tolerance?Anne S De Groot
EpiVax, Inc, Providence, RI 02903, USA
Cell Immunol 244:148-53. 2006..Over evolutionary timescales, immune pressure may have resulted in alterations in the inherent T-cell immunogenic potential of autologous proteins...
Immunogenicity of protein therapeuticsAnne S De Groot
EpiVax, Inc, 146 Clifford Street, Providence, RI 02903, USA
Trends Immunol 28:482-90. 2007..Here, we review some theories put forward to explain the immunogenicity of therapeutic proteins and describe some emerging protein-engineering approaches that might prevent the development of anti-drug antibodies...
Mapping cross-clade HIV-1 vaccine epitopes using a bioinformatics approachAnne S De Groot
TB HIV Research Lab, Brown University, Providence, RI 02912, USA
Vaccine 21:4486-504. 2003..Putative HIV-1 CTL epitopes were selected from this list using the epitope prediction tool EpiMatrix...
Diversity of Francisella tularensis Schu4 antigens recognized by T lymphocytes after natural infections in humans: identification of candidate epitopes for inclusion in a rationally designed tularemia vaccineJulie A McMurry
EpiVax, Inc, Providence, RI 02903, USA
Vaccine 25:3179-91. 2007..These data can aid in the development of novel epitope-based and subunit tularemia vaccines...
Immuno-informatics: Mining genomes for vaccine componentsAnne S De Groot
TB HIV Research Laboratory, Brown University, Providence, Rhode Island 02912, USA
Immunol Cell Biol 80:255-69. 2002..The present article reviews the work of several groups engaged in the development of immuno-informatics tools and illustrates the application of these tools to the process of vaccine discovery...
Engineering immunogenic consensus T helper epitopes for a cross-clade HIV vaccineAnne S De Groot
TB HIV Research Lab, Brown University, Providence RI 02912, USA
Methods 34:476-87. 2004..These data confirm the utility of bioinformatics tools to select and construct novel "immunogenic consensus sequence" T cell epitopes for a globally relevant vaccine against HIV...
T cell epitope identification for bovine vaccines: an epitope mapping method for BoLA A-11Anne S De Groot
EpiVax, Inc 16 Bassett Street, Providence RI 02903, USA
Int J Parasitol 33:641-53. 2003..Furthermore, using epitope-mapping algorithms, putative T cell epitopes can be derived directly from genomic sequences, allowing researchers to circumvent labor-intensive cloning steps in the genome-to-vaccine discovery pathway...
Epitope-based vaccination against pneumonic tularemiaStephen H Gregory
Rhode Island Hospital and The Warren Alpert Medical School of Brown University, Providence, RI, United States
Vaccine 27:5299-306. 2009..These results demonstrate the efficacy of an epitope-based tularemia vaccine and suggest that such an approach might be widely applicable to the development of vaccines specific for intracellular bacterial pathogens...
Novel function of complement C3d as an autologous helper T-cell targetPaul M Knopf
Department of Molecular Microbiology and Immunology, Brown University, Providence, RI 02912, USA
Immunol Cell Biol 86:221-5. 2008..We believe that the discovery of these autologous T cells autoreactive for C3d provides evidence supporting the 'co-signal 2' hypothesis and may offer a novel explanation of the CD21 KO paradox...
Activation of natural regulatory T cells by IgG Fc-derived peptide "Tregitopes"Anne S De Groot
EpiVax, Providence, RI, USA
Blood 112:3303-11. 2008..In this model, regulatory T-cell epitopes in IgG activate a subset of nT(Regs) that tips the resulting immune response toward tolerance rather than immunogenicity...
The role of glutamic or aspartic acid in position four of the epitope binding motif and thyrotropin receptor-extracellular domain epitope selection in Graves' diseaseHidefumi Inaba
Department of Cellular and Molecular Biology, University of Rhode Island, 80 Washington Street, Providence, Rhode Island 02903, USA
J Clin Endocrinol Metab 95:2909-16. 2010..Development of Graves' disease (GD) is related to HLA-DRB1*0301 (DR3),and more specifically to arginine at position 74 of the DRB1 molecule. The extracellular domain (ECD) of human TSH receptor (hTSH-R) contains the target antigen...
Epitope-driven TB vaccine development: a streamlined approach using immuno-informatics, ELISpot assays, and HLA transgenic miceJulie A McMurry
EpiVax Inc, 146 Clifford Street, Providence RI 02903, USA
Curr Mol Med 7:351-68. 2007..These experiments illustrate the use of immuno-informatics tools for vaccine development and describe a pathway for the development of a more effective, epitope-driven, immunotherapeutic vaccine for TB...
In silico-accelerated identification of conserved and immunogenic variola/vaccinia T-cell epitopesLeonard Moise
EpiVax, Inc, Providence, RI, USA
Vaccine 27:6471-9. 2009..This experimental validation of computational predictions illustrates the potential for immunoinformatics methods to identify candidate immunogens for a new, safer smallpox vaccine...
A call to cellular & humoral arms: enlisting cognate T cell help to develop broad-spectrum vaccines against influenza AJulie A McMurry
EpiVax, Inc, Vaccines Division, Providence, Rhode Island 02903, USA
Hum Vaccin 4:148-57. 2008..This review summarizes the critical components of effective influenza vaccines, a rational vaccine design approach, and the pertinent influenza immunology...
Developing an epitope-driven tuberculosis (TB) vaccineAnne S De Groot
EpiVax, Inc, Providence, RI 02903, USA
Vaccine 23:2121-31. 2005..The systematic application of bioinformatics tools to whole genomes, in combination with in vitro methods for screening and confirming epitopes, may lead to the development of novel vaccines for infectious diseases like TB...
Identification of genome-derived vaccine candidates conserved between human and mouse-adapted strains of H. pyloriLeonard Moise
Brown University, Providence, Rhode Island, USA
Hum Vaccin 4:219-23. 2008..pylori isolates J99 and 26695 are conserved in SS1. Epitopes conserved in SS1 were further analyzed for binding to MHC in vitro and for antigenicity in infected mice to select candidates for an epitope-based vaccine...
From immunome to vaccine: epitope mapping and vaccine design toolsAnne S De Groot
TB/HIV Research Laboratory, Brown University, International Health Institute, Box GB473, Providence, RI 02912, USA
Novartis Found Symp 254:57-72; discussion 72-6, 98-101, 250-2. 2003..More recent applications of the tools involve deriving novel vaccine candidates directly from whole genomes, an approach that has been named 'genome to vaccine'...
Tularemia vaccines - an overviewJulie A McMurry
EpiVax, Inc, Providence, RI 02903, USA
Med Health R I 90:311-4. 2007....
Vaccine renaissance--from basic research to implementationAnne S De Groot
EpiVax, Providence, RI 02903, USA
Med Health R I 90:300. 2007
VennVax, a DNA-prime, peptide-boost multi-T-cell epitope poxvirus vaccine, induces protective immunity against vaccinia infection by T cell response aloneLeonard Moise
EpiVax, Inc, Providence, RI, USA
Vaccine 29:501-11. 2011..Remarkably, 100% of vaccinated mice survived lethal vaccinia challenge, demonstrating that protective immunity to vaccinia does not require B cell priming...
Bioinformatics tools for identifying class I-restricted epitopesWilliam Martin
EpiVax, Inc, Providence, Rhode Island, USA
Methods 29:289-98. 2003..CTL epitopes discovered using these tools might be used to develop novel vaccines and therapeutics for the prevention and treatment of infectious diseases such as human immunodeficiency virus, hepatitis C, tuberculosis, and some cancers...
Genome-derived vaccinesAnne S De Groot
TB HIV Research Laboratory, Brown University, Providence, RI 20903, USA
Expert Rev Vaccines 3:59-76. 2004..This article addresses the convergence of three forces--microbial genome sequencing, computational immunology and new vaccine technologies--that are shifting genome mining for vaccines onto the forefront of immunology research...
T cell epitope: friend or foe? Immunogenicity of biologics in contextConstanze A Weber
EpiVax, Providence, RI 02903, USA
Adv Drug Deliv Rev 61:965-76. 2009..In this review, we address the application of computational tools for preclinical immunogenicity assessment, the implication of the discovery of regulatory T cell epitopes, and experimental validation of those assessments...
Progress towards a genome-derived, epitope-driven vaccine for latent TB infectionLeonard Moise
EpiVax, Inc, Providence, RI, USA
Med Health R I 90:301-3. 2007
Thyrotropin receptor epitopes and their relation to histocompatibility leukocyte antigen-DR molecules in Graves' diseaseHidefumi Inaba
Brown University/Medicine/Endocrinology, Box G, Room E-308, 70 Ship Street, Providence, Rhode Island 02903, USA
J Clin Endocrinol Metab 91:2286-94. 2006..However, peptide 132-150 (GIFNTGLKMFPDLTKVYST) was identified by three methods as an important epitope in GD; the possible importance of peptides 145-163, 158-176, 207-222, 248-263, 272-291, and 343-362 was also identified...
How the SARS vaccine effort can learn from HIV-speeding towards the future, learning from the pastAnne S De Groot
TB HIV Research Laboratory, Brown University, Providence, RI 02912, USA
Vaccine 21:4095-104. 2003..This article reviews parallels between HIV and SARS and proposes an approach that would accelerate the development of a SARS vaccine...
Research Grants
- Optimization of a Multivalent Tuberculosis VaccineAnne De Groot; Fiscal Year: 2007..Successful completion of this work will set the stage for Phase II development that will partner the vaccine with improved recombinant BCG vaccines and assess efficacy in additional strains of HLA transgenic mice. ..
- Epitope-driven deimmunization of Factor VIIIAnne De Groot; Fiscal Year: 2007..The proposed reengineered protein will be evaluated in a mice that have a hemophilia as well as in mice that have a human- like immune system. ..
- Development of De-immunized Botulinum Neurotoxin Type A for DystoniaAnne De Groot; Fiscal Year: 2007..Public Health Relatedness: Knowledge of the elements of botulinum neurotoxin type A that give rise to its immunogenicity will contribute to the development of improved dystonia therapy. ..
- 2nd Annual Vaccine Renaissance Conference, RIAnne De Groot; Fiscal Year: 2006..This 2nd Annual conference follows a highly successful 1st Annual Vaccine Renaissance, RI that took place on June 8, 9 2005. More than 80 participants attended that 1st conference from the New England region and beyond. ..
- Epitope Driven HIV Vaccine DevelopmentAnne De Groot; Fiscal Year: 2005..The final product of this joint effort will be a set of plasmids to be combined in an epitope-driven, oligonucleotide-based DNA cocktail vaccine for HIV. ..
- A Genome-Derived, Epitope-Driven H. Pylori VaccineAnne De Groot; Fiscal Year: 2006..pylori disease as our correlate of efficacy. ..
- Novel Smallpox Vaccine Derived from VV/VAR ImmunomeAnne De Groot; Fiscal Year: 2006....
- A GENOME-DERIVED, EPITOPE-DRIVEN TULAREMIA VACCINEAnne De Groot; Fiscal Year: 2005..abstract_text> ..
